AGT Gene Test (Angiotensinogen)

• Identify whether you carry AGT variants such as M235T and T174M that influence angiotensinogen levels and are associated with blood pressure regulation and cardiovascular risk in many populations.
• Help explain a tendency toward higher blood pressure, earlier onset hypertension, or more difficult-to-control readings despite lifestyle adjustments.
• Inform personalised strategies around salt and fluid intake, exercise, weight management, and how intensively to monitor and manage blood pressure over time.
• Provide context for cardiovascular and kidney risk in the presence of other factors such as dyslipidaemia, diabetes, family history, and pregnancy-related blood pressure changes.
• Clarify your baseline renin--angiotensin profile alongside blood pressure, metabolic markers, and lifestyle data, so long-term heart, vessel, and brain health plans can be built around your biology.

AGT encodes angiotensinogen, a liver-produced precursor protein that sits at the top of the renin--angiotensin system, a hormone cascade that regulates blood pressure, fluid volume, and electrolyte balance. When blood pressure or kidney perfusion falls, the kidney secretes renin, which cleaves angiotensinogen to angiotensin I.

Angiotensin I is then converted by angiotensin-converting enzyme into angiotensin II, a potent vasoconstrictor that narrows blood vessels, raises blood pressure, stimulates aldosterone release from the adrenal glands, and promotes renal sodium and water reabsorption. Through these actions, the AGT gene product plays a central role in maintaining circulatory stability and is implicated in the development of essential hypertension and related cardiovascular diseases.

AGT sits at the upstream gate of the renin--angiotensin system. The amount and activity of angiotensinogen produced by the liver help determine how much angiotensin I and II can be generated when renin is released. Higher angiotensinogen levels generally increase the capacity of the system to raise blood pressure and promote sodium retention when activated.

Common AGT polymorphisms, such as M235T, influence circulating angiotensinogen levels and have been associated in many studies with susceptibility to essential hypertension, malignant hypertension in some groups, and increased risk of coronary artery disease when combined with other risk factors like dyslipidaemia. Rare mutations can also cause renal tubular dysgenesis, a severe developmental kidney disorder, though this is distinct from common adult-onset patterns.

AGT contributes to three interconnected systems: blood pressure control, cardiovascular and kidney health, and metabolic and pregnancy-related outcomes. Chronic activation of the renin--angiotensin system through genetic and environmental factors can lead to sustained vasoconstriction, sodium retention, and structural changes in blood vessels and the heart.

Over time, this increases the risk of hypertension, left ventricular hypertrophy, atherosclerosis, heart failure, stroke, chronic kidney disease, and complications such as preeclampsia in pregnancy. AGT variants that raise angiotensinogen levels may tilt the system toward higher baseline activity, which becomes especially relevant in the presence of high salt intake, obesity, insulin resistance, or other cardiovascular stressors.

It is easy to assume that AGT genotyping and blood pressure readings or cardiovascular tests provide the same information, but they answer different questions. AGT genotyping looks at inherited difference in angiotensinogen production and renin--angiotensin sensitivity, which remains constant throughout life.

Blood pressure measurements, ECGs, echocardiograms, and kidney function tests show how your cardiovascular and renal systems are performing right now under your existing diet, activity, and treatment. You can carry higher-risk AGT variants and still have normal blood pressure if lifestyle and other genes are favourable, and conversely you can develop hypertension without AGT risk variants if salt intake, weight, stress, or other factors push the system hard enough. Together, genotype and phenotypic data provide a more complete picture of risk and trajectory.

The influence of AGT variants is shaped by salt intake, body composition, metabolic status, and wider vascular and kidney health far more than by the gene alone. Several modifiable factors can either buffer genetic effects or amplify them.

• Dietary salt and fluid intake: High salt intake raises blood pressure more strongly in some AGT genotypes, especially those associated with higher angiotensinogen levels. Moderating salt and aligning fluid intake with needs can significantly reduce risk.
• Body weight and visceral fat: Obesity and central adiposity increase renin--angiotensin system activity and sympathetic drive. In carriers of AGT risk variants, excess weight amplifies hypertension risk and vascular stress.
• Physical activity and cardiorespiratory fitness: Regular exercise improves vascular function, autonomic balance, and metabolic health, helping counteract AGT-driven tendencies toward higher blood pressure.
• Insulin resistance and dyslipidaemia: Elevated insulin, triglycerides, and adverse lipid patterns interact with AGT-driven vascular and renal changes to accelerate atherosclerosis and coronary risk.
• Kidney health and renal artery status: Kidney disease and renal artery issues can drive renin--angiotensin activation. In people with AGT variants, this combination can create particularly strong blood pressure responses.
• Pregnancy and hormonal status: The renin--angiotensin system is active in pregnancy, and AGT variants are implicated in preeclampsia risk in some studies. Hormones, contraceptives, and menopause also interact with blood pressure regulation.

Yes. Many people with AGT variants, including M235T and T174M, never develop hypertension or cardiovascular disease, especially if they maintain healthy weight, diet, and activity, and avoid smoking. The gene modifies risk; it does not guarantee a specific outcome.

In those who do develop hypertension, early changes often appear as mild elevation in blood pressure without symptoms. Headaches, fatigue, or palpitations are not specific and may appear later or not at all. Undetected high blood pressure can quietly damage blood vessels, heart, kidneys, and brain over years, which is why regular monitoring is important regardless of genotype.

AGT genotypes mainly differ in how they influence angiotensinogen levels and, in turn, the activity of the renin--angiotensin system. Understanding your pattern helps tailor lifestyle changes and, in some cases, informs clinical thinking about blood pressure and cardiovascular risk.

• M235T polymorphism (rs699): Substitution at amino acid 235 has been associated in many cohorts with higher circulating angiotensinogen and increased risk of essential hypertension. The TT genotype in some populations shows stronger associations with malignant hypertension and coronary artery disease when combined with other risk factors.
• T174M polymorphism: This variant has been linked in some studies to coronary artery disease and blood pressure variation, though findings are not entirely consistent across populations. Its impact is often considered alongside M235T.
• Promoter and regulatory variants: Changes upstream of the AGT coding region can affect transcription rates, altering baseline angiotensinogen levels and contributing to inter-individual differences in blood pressure regulation.
• Rare loss-of-function or severe variants: Biallelic severe AGT mutations can cause renal tubular dysgenesis, a rare and serious developmental disorder; this is distinct from the common polymorphisms considered in adult cardiovascular risk profiling.

For DNA-based AGT testing, preparation is straightforward because your genotype does not change with blood pressure, diet, or medication use. The key step is clarifying how the results will be used, for example to understand personal and family blood pressure risk or to inform a detailed cardiovascular prevention plan.

Cheek swab, saliva, or blood-based AGT genotyping does not require fasting. If you are combining AGT testing with blood pressure assessments, lipids, glucose, kidney function, or hormone tests, follow the specific preparation instructions for those tests, such as fasting or morning sampling.

An AGT test is most helpful when the result will influence how you monitor and manage blood pressure and cardiovascular risk, rather than as a curiosity. It becomes particularly informative when combined with regular blood pressure data, metabolic labs, and family history.

• Early-onset or resistant hypertension: If blood pressure is high at a relatively young age, or remains elevated despite lifestyle efforts and standard medication, AGT genotyping can add context to why your system may be more pressure-sensitive.
• Strong family history of hypertension or cardiovascular events: In families where high blood pressure, heart attacks, or strokes cluster, AGT and other cardiovascular genes help clarify risk and support earlier, more proactive prevention.
• Pregnancy planning or history of preeclampsia: For individuals with personal or family history of hypertensive disorders of pregnancy, AGT status may form part of a detailed risk review and monitoring plan.
• Comprehensive performance and longevity strategy: For those building a full-profile approach to heart, brain, and kidney health, AGT sits alongside other renin--angiotensin genes and cardiometabolic markers in shaping life-long decisions.